Evidence map›Paper›PMID 40365291›Full record

ArticleTheranostics2025

Bispecific Siglec-15/T cell antibody (STAB) activates T cells and suppresses pancreatic ductal adenocarcinoma and non-small cell lung tumors

Limei Shen, Alison Schaefer, Justin Huckaby, Whitney Wolf, Samuel K Lai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Limei ShenDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA.
Alison SchaeferDepartment of Biomedical Engineering, University of North Carolina at Chapel Hill, NC, USA.
Justin HuckabyDepartment of Biomedical Engineering, University of North Carolina at Chapel Hill, NC, USA.
Whitney WolfDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA.
Samuel K LaiDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Engineering Siglec15/TGF-beta targeted bispecific antibodies that modulate the tumor microenvironment and enhances T-cell immunotherapy against pancreatic cancerR21CA273983 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAI, SAMUEL · 2023 to 2024
$384k
NCI NIH HHS P30 CA016086NCI NIH HHS R21 CA273983
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, BispecificCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalLectinsLung NeoplasmsMembrane ProteinsPancreatic NeoplasmsT-LymphocytesAnimalsCD3 ComplexCell Line, TumorFemaleHumansImmunoglobulinsImmunotherapyLymphocyte ActivationAntibodies, BispecificCD3 ComplexImmunoglobulinsLectinsMembrane ProteinsSIGLEC15 protein, humanbispecific T cell engager (biTE)immunotherapytumor microenvironment

Identifiers

PMID40365291
PMCPMC12068307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.